<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): December 23, 2008</B>


<P style="font-size: 24pt" align="center"><B>IMMTECH PHARMACEUTICALS,
INC.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>001-14907</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>39-1523370</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>One North End Avenue<BR>
New
York, New York <BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>10282</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(212) 791-2911</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>



<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>ITEM 3.01 Notice of Delisting or
Failure to Satisfy a Continued Listing Rule or Standard; Transfer of
Listing.</B>

<P style="font-size: 10pt; text-indent: 7%" align="left">On December&nbsp;23,
2008, Immtech Pharmaceuticals, Inc. (the &#8220;Company&#8221;) received a
notice from the staff from the NYSE Alternext US (the &#8220;Exchange&#8221;)
that a review of the Company&#8217;s quarterly report on Form 10-Q for the
period ended September&nbsp;30, 2008 indicated that the Company is not in
compliance with certain of the Exchange&#8217;s continued listing standards as
set forth in the Exchange&#8217;s Company Guide (the &#8220;Company
Guide&#8221;).

<P style="font-size: 10pt; text-indent: 7%" align="left">Specifically, the
Exchange noted that the Company is not in compliance with
(a)&nbsp;Section&nbsp;1003(a)(ii) of the Company Guide, because its
stockholders&#8217; equity is less than $4,000,000 and it has had losses from
continuing operations and net losses in three out of its four most recent
fiscal years; (b)&nbsp;Section&nbsp;1003(a)(iii) of the Company Guide, because
its stockholders&#8217; equity is less than $6,000,000 and it has had losses
from continuing operations and net losses in its five most recent fiscal years;
and (c)&nbsp;Section&nbsp;1003(a)(iv) of the Company Guide, because it has
sustained losses which are so substantial in relation to its overall operations
or its existing financial resources, or its financial condition has become so
impaired that it appears questionable, in the opinion of the Exchange, as to
whether the Company will be able to continue operations and/or meet its
obligations as they mature.

<P style="font-size: 10pt; text-indent: 7%" align="left">In order to maintain
listing of the Company&#8217;s common stock on the Exchange, the Company must
submit a plan by January&nbsp;23, 2009, advising the Exchange of how the
Company intends to regain compliance with Section&nbsp;1003(a)(iv) of the
Company Guide by March&nbsp;23, 2009 and Sections&nbsp;1003(a)(ii) and
(iii)&nbsp;of the Company Guide by June&nbsp;23, 2010. If the Exchange accepts
the plan, the Company may be able to continue its listing during the plan
period up to June&nbsp;23, 2010, during which time the Company will be subject
to periodic reviews to determine whether it is making progress consistent with
the plan. If the Exchange does not accept the Company&#8217;s plan, or even if
accepted, if the Company is not in compliance with all the continued listing
standards at the end of the plan period or the Company does not make progress
consistent with the plan during such period, then the Exchange may initiate
delisting proceedings.

<P style="font-size: 10pt; text-indent: 7%" align="left">The Company presently
intends to submit such a plan for the Exchange to review by January&nbsp;23,
2009. The Company&#8217;s common stock continues to trade on the Exchange;
however, the Company will become subject to the trading symbol extension
&#8220;.BC&#8221; to denote noncompliance with the continued listing standards.
Within five days of the December&nbsp;23, 2008 letter from the Exchange, the
Company will be included in a list on the Exchange website of issuers that are
not in compliance with the listing standards. The &#8220;.BC&#8221; indicator
will remain as an extension on the Company&#8217;s trading symbol until the
Company has regained compliance with all applicable continued listing standards.

<P style="font-size: 10pt" align="left"><B>ITEM 9.01 Financial Statements and
Exhibits.</B>

<P style="font-size: 10pt" align="left">(d)&nbsp;Exhibits

<P style="font-size: 10pt" align="left">The following exhibits are filed
herewith:
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD style="border-bottom: #000000 1px solid" nowrap
align="left"><B>No.</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid" nowrap
align="center"><B>Exhibit</B></TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press release, dated December&nbsp;30, 2008,
announcing receipt of Notice from NYSE Alternext US for Non-Compliance with
Continued Listing Criteria.</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt; text-indent: 7%" align="left">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.

<P style="font-size: 10pt" align="left">Date: December&nbsp;30, 2008

<P style="font-size: 10pt; margin-left: 46%; MARGIN-TOP: -11PT" align="left"><B>IMMTECH
PHARMACEUTICALS, INC.</B>

<P style="font-size: 10pt; margin-left: 46%" align="left"><U>/s/ Eric L.
Sorkin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Eric
L. Sorkin<BR>
Chairman, Chief Executive Officer and President<BR>


<P style="font-size: 10pt" align="center">&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><U><B>EXHIBIT INDEX</B></U>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD style="border-bottom: #000000 1px solid" nowrap
align="left"><B>No.</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid" nowrap
align="center"><B>Exhibit</B></TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press release, dated December&nbsp;30, 2008,
announcing receipt of Notice from NYSE Alternext US for Non-Compliance with
Continued Listing Criteria.</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c78847e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 11289}]
{"company-data": {"conformed-name": "IMMTECH PHARMACEUTICALS, INC.", "cik": "0000882509", "assigned-sic": "2836", "irs-number": "391523370", "state-of-incorporation": "DE", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14907", "film-number": "081276434"}, "business-address": {"street1": "150 FAIRWAY DRIVE", "street2": "SUITE 150", "city": "VERNON HILLS", "state": "IL", "zip": "60061", "phone": "(847) 573-0033"}, "mail-address": {"street1": "150 FAIRWAY DRIVE", "street2": "SUITE 150", "city": "VERNON HILLS", "state": "IL", "zip": "60061"}, "former-company": {"former-conformed-name": "IMMTECH INTERNATIONAL INC", "date-changed": "19980824"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): December 23, 2008
IMMTECH PHARMACEUTICALS,
INC.
(Exact name of registrant as
specified in its charter)
Delaware
001-14907
39-1523370
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One North End Avenue
New
York, New York
10282
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
(212) 791-2911
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 3.01 Notice of Delisting or
Failure to Satisfy a Continued Listing Rule or Standard; Transfer of
Listing.
On December 23,
2008, Immtech Pharmaceuticals, Inc. (the "Company") received a
notice from the staff from the NYSE Alternext US (the "Exchange")
that a review of the Company's quarterly report on Form 10-Q for the
period ended September 30, 2008 indicated that the Company is not in
compliance with certain of the Exchange's continued listing standards as
set forth in the Exchange's Company Guide (the "Company
Guide").
Specifically, the
Exchange noted that the Company is not in compliance with
(a) Section 1003(a)(ii) of the Company Guide, because its
stockholders' equity is less than $4,000,000 and it has had losses from
continuing operations and net losses in three out of its four most recent
fiscal years; (b) Section 1003(a)(iii) of the Company Guide, because
its stockholders' equity is less than $6,000,000 and it has had losses
from continuing operations and net losses in its five most recent fiscal years;
and (c) Section 1003(a)(iv) of the Company Guide, because it has
sustained losses which are so substantial in relation to its overall operations
or its existing financial resources, or its financial condition has become so
impaired that it appears questionable, in the opinion of the Exchange, as to
whether the Company will be able to continue operations and/or meet its
obligations as they mature.
In order to maintain
listing of the Company's common stock on the Exchange, the Company must
submit a plan by January 23, 2009, advising the Exchange of how the
Company intends to regain compliance with Section 1003(a)(iv) of the
Company Guide by March 23, 2009 and Sections 1003(a)(ii) and
(iii) of the Company Guide by June 23, 2010. If the Exchange accepts
the plan, the Company may be able to continue its listing during the plan
period up to June 23, 2010, during which time the Company will be subject
to periodic reviews to determine whether it is making progress consistent with
the plan. If the Exchange does not accept the Company's plan, or even if
accepted, if the Company is not in compliance with all the continued listing
standards at the end of the plan period or the Company does not make progress
consistent with the plan during such period, then the Exchange may initiate
delisting proceedings.
The Company presently
intends to submit such a plan for the Exchange to review by January 23,
2009. The Company's common stock continues to trade on the Exchange;
however, the Company will become subject to the trading symbol extension
".BC" to denote noncompliance with the continued listing standards.
Within five days of the December 23, 2008 letter from the Exchange, the
Company will be included in a list on the Exchange website of issuers that are
not in compliance with the listing standards. The ".BC" indicator
will remain as an extension on the Company's trading symbol until the
Company has regained compliance with all applicable continued listing standards.
ITEM 9.01 Financial Statements and
Exhibits.
(d) Exhibits
The following exhibits are filed
herewith:
No.
Exhibit
99.1
Press release, dated December 30, 2008,
announcing receipt of Notice from NYSE Alternext US for Non-Compliance with
Continued Listing Criteria.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Date: December 30, 2008
IMMTECH
PHARMACEUTICALS, INC.
/s/ Eric L.
Sorkin
Eric
L. Sorkin
Chairman, Chief Executive Officer and President
EXHIBIT INDEX
No.
Exhibit
99.1
Press release, dated December 30, 2008,
announcing receipt of Notice from NYSE Alternext US for Non-Compliance with
Continued Listing Criteria.